Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases

Abstract

<b><i>Introduction:</i></b> Prostatic stromal tumor of uncertain malignant potential (STUMP) is a rare disease that may coexist with prostate stromal sarcoma (PSS). We aimed to analyze the histological and clinical features of STUMP. <b><i>Methods:</i></b> Twenty-three patients diagnosed with STUMP from 2008 to 2019 were included. Clinicopathological and follow-up information was collected. In the subgroup analysis, we divided the patients into a pure STUMP group (<i>N</i> = 18) and a mixed STUMP (STUMP coexisting with PSS) group (<i>N</i> = 5). Student’s <i>t</i> test was used to compare the 2 groups. <b><i>Results:</i></b> Patients had a mean age of 55.5 ± 19.4 years and an average follow-up time of 42.3 months. The mean prostate volume was 109.2 ± 73.5 cm³, and the mean prostate-specific antigen was 8.03 ± 10.5 ng/mL. In the subgroup analysis, 16.7% (2/12) of pure STUMP patients had disease progression, while 100% (3/3) of mixed STUMP patients suffered from recurrence. Compared with the pure STUMP group, the mixed STUMP group was younger (37.2 vs. 60.6 years, <i>p</i> = 0.013) and had lower expression of estrogen receptor and progesterone receptor (<i>p</i> = 0.004 and <i>p</i> &#x3c; 0.001, respectively). <b><i>Conclusion:</i></b> STUMP is a rare disease with a relatively good prognosis. However, there is still a possibility of disease progression or coexistence with stromal sarcoma. Timely diagnosis and regular monitoring may be helpful in improving treatment outcomes.